An Update on Medical Management of Thyroid Eye Disease with Insights on Teprotumumab
Thyroid eye disease (TED) is a debilitating autoimmune condition. It occurs most commonly with the hyperthyroid state but can also be seen in euthyroid and hypothyroid states. Corticosteroids, steroid-sparing agents, and biologicals have been used, although none of them were Food and Drug Administra...
Saved in:
| Main Authors: | Smriti Dabas, Nishi Meghna Satish, Sangeeta Abrol |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-07-01
|
| Series: | Delhi Journal of Ophthalmology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/DLJO.DLJO_131_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Teprotumumab and sensorineural hearing loss: a propensity score-matched retrospective cohort study
by: Maxim John Levy Barnett, et al.
Published: (2025-07-01) -
Radiological Features of Thyroid Eye Disease (TED)
by: Ayushi Agarwal, et al.
Published: (2020-10-01) -
Evolving techniques in orbital decompression of thyroid orbitopathy
by: Manuel O. Palmero, MD, et al.
Published: (2007-06-01) -
The role of IL-6 in thyroid eye disease: an update on emerging treatments
by: Jennifer Murdock, et al.
Published: (2025-04-01) -
Teprotumumab in the management of thyroid eye disease mechanistic insights and adverse reactions: a comprehensive review
by: Zhibin Xu, et al.
Published: (2025-05-01)